RAPT's Chief Medical Officer Gets Major Equity Stake in Biotech's Future

Rhea-AI Filing Summary

RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:

• Grant of 75,000 employee stock options
• Exercise price set at $7.43 per share
• Options expire on June 19, 2035
• Vesting schedule: 1/48th of shares vest monthly from June 20, 2025

This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HO WILLIAM

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	75,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 75,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HO WILLIAM

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$7.43	06/20/2025		A		75,000		(1)	06/19/2035	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.

	/s/ Rodney Young, Attorney-in-Fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options were granted to RAPT Therapeutics' Chief Medical Officer William Ho in June 2025?

William Ho was granted 75,000 employee stock options on June 20, 2025, with an exercise price of $7.43 per share. These options expire on June 19, 2035.

What is the vesting schedule for William Ho's RAPT stock options granted in June 2025?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month following the vesting commencement date of June 20, 2025.

Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?

The Form 4 was filed for William Ho, RAPT Therapeutics' Chief Medical Officer, and was signed by Rodney Young as Attorney-in-Fact on June 24, 2025.

What is the total value of RAPT stock options granted to William Ho in June 2025?

William Ho received options to purchase 75,000 shares of RAPT common stock at an exercise price of $7.43 per share. The options were granted at $0 cost to Ho as part of his compensation package.